|February 14, 2013|
|13:55 EDT||JNJ||Johnson & Johnson recalling thousands of hip implants, AP reports|
Johnson & Johnson (JNJ) is recalling thousands of Adept hip implants almost three years after a similar recall, the Associated Press reports, citing German newspaper Handelsblatt. The hip implants, made by J&J's DePuy Orthopaedics unit, showed a failure rate of 12% after seven years. Reference Link
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
|December 9, 2013|
|19:06 EDT||JNJ||J&J's Janssen reports ibrutinib met primary endpoint of safety|
Janssen announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events that were predominantly Grade 1 or 2 in nature. Efficacy data were also collected and showed that 71% of patients treated with ibrutinib achieved an objective response. Although estimates of progression-free survival and overall survival were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.
|07:01 EDT||JNJ||Myriad Genetics announces cancer research collaboration with Janssen|
Subscribe for More Information
|December 8, 2013|
|18:45 EDT||JNJ||J&J's siltuximab improves symptoms in Castleman disease, Bloomberg says |
Subscribe for More Information
|December 5, 2013|
|07:59 EDT||JNJ||Cooper Companies added to Select List at Stifel|
Stifel added Cooper Companies (COO) to its Select List after surveying 36 optometry practices in the U.K. The firm reports that Cooper's new silicone hydrogel daily lens, MyDay, appears to be performing well in the country, and is ranked ahead of J&J's (JNJ) competing TruEye by optometrists there. The firm keeps a $150 price target and Buy rating on Cooper.
|December 4, 2013|
|16:51 EDT||JNJ||Johnson & Johnson unit to pay $1.25M to settle with FDA|
The U.S. Food and Drug Administration has reached a $1.25M settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon, a Johnson & Johnson company, and two of ASP’s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products. The settlement requires ASP to pay $1.2M, company president Bernard Zovighian to pay $30,000, and company VP of quality and regulatory compliance Richard Alberti to pay $20,000. Reference Link
|December 3, 2013|
|08:56 EDT||JNJ||LabCorp announces availability of enhanced HCV GenoSure NS3/4|
Laboratory Corporation (LH) announced the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics’ (JNJ) OLYSIO, which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
|November 27, 2013|
|13:21 EDT||JNJ||J&J may pay $1B in medical costs under hip settlement, Bloomberg says|
Johnson & Johnson may have to pay up to $1B to insurers who covered the medical costs of removing its recalled hip implants under the settlement announced previously, says Bloomberg. Reference Link